A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Sialorrhoea

Interventions

DRUG: oxybutynin and clonidine oral solution treatment A
DRUG: oxybutynin and clonidine oral solution treatment B
DRUG: oxybutynin and clonidine oral solution treatment C
DRUG: oxybutynin and clonidine oral solution treatment D

Sponsor

Orient Pharma Co., Ltd.